These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. Pricing for orphan drugs: will the market bear what society cannot? O'Sullivan BP; Orenstein DM; Milla CE JAMA; 2013 Oct; 310(13):1343-4. PubMed ID: 24084916 [No Abstract] [Full Text] [Related]
64. New Drugs 2019, part 1. Hussar DA Nursing; 2019 Feb; 49(2):28-36. PubMed ID: 30676555 [TBL] [Abstract][Full Text] [Related]
65. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies. McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001 [TBL] [Abstract][Full Text] [Related]
66. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator. Ong T; Ramsey BW Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186 [TBL] [Abstract][Full Text] [Related]
67. The impact of 12 months treatment with ivacaftor on Scottish paediatric patients with cystic fibrosis with the G551D mutation: a review. Dryden C; Wilkinson J; Young D; Brooker RJ; Arch Dis Child; 2018 Jan; 103(1):68-70. PubMed ID: 27288428 [TBL] [Abstract][Full Text] [Related]
68. Update in Cystic Fibrosis 2014. Ong T; Ramsey BW Am J Respir Crit Care Med; 2015 Sep; 192(6):669-75. PubMed ID: 26371812 [No Abstract] [Full Text] [Related]
69. The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis. Talamo Guevara M; McColley SA Expert Opin Drug Saf; 2017 Nov; 16(11):1305-1311. PubMed ID: 28846049 [TBL] [Abstract][Full Text] [Related]
70. Foundation receives $3.3-billion windfall for Kalydeco. Senior M Nat Biotechnol; 2015 Jan; 33(1):8-9. PubMed ID: 25574617 [No Abstract] [Full Text] [Related]
71. Cystic fibrosis: a review of pathophysiology and current treatment recommendations. Peters S S D Med; 2014 Apr; 67(4):148-51, 153. PubMed ID: 24791377 [No Abstract] [Full Text] [Related]
72. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis. McPhail GL; Clancy JP Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952 [TBL] [Abstract][Full Text] [Related]
73. A safety evaluation of ivacaftor for the treatment of cystic fibrosis. McColley SA Expert Opin Drug Saf; 2016 May; 15(5):709-15. PubMed ID: 26968005 [TBL] [Abstract][Full Text] [Related]
74. Cystic fibrosis in 2016: considerable progress, but much more to do. Davies JC Lancet Respir Med; 2016 Dec; 4(12):943-945. PubMed ID: 27890501 [No Abstract] [Full Text] [Related]
75. The Role of Ivacaftor in Severe Cystic Fibrosis in a Patient With the R117H Mutation. Ronan NJ; Fleming C; O'Callaghan G; Maher MM; Murphy DM; Plant BJ Chest; 2015 Sep; 148(3):e72-e75. PubMed ID: 26324139 [TBL] [Abstract][Full Text] [Related]
76. Lumacaftor/Ivacaftor in Patients Aged 6-11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR. Milla CE; Ratjen F; Marigowda G; Liu F; Waltz D; Rosenfeld M; Am J Respir Crit Care Med; 2017 Apr; 195(7):912-920. PubMed ID: 27805836 [TBL] [Abstract][Full Text] [Related]
77. 50 years ago in The Journal of Pediatrics: The use of N-acetylcysteine in the treatment of cystic fibrosis. Cantu-Gonzalez G J Pediatr; 2014 Oct; 165(4):721. PubMed ID: 25256050 [No Abstract] [Full Text] [Related]
78. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects. Kuk K; Taylor-Cousar JL Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827 [TBL] [Abstract][Full Text] [Related]
79. Update in cystic fibrosis 2013. Jain M; Goss CH Am J Respir Crit Care Med; 2014 May; 189(10):1181-6. PubMed ID: 24832742 [No Abstract] [Full Text] [Related]
80. Clinical trial research in focus: ensuring new cystic fibrosis drugs fulfil their potential. Elborn JS; Davies J Lancet Respir Med; 2017 Sep; 5(9):681-683. PubMed ID: 28853396 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]